LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.

@article{Pietersz2001LFA1AI,
  title={LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.},
  author={Geoffrey A. Pietersz and Mauro Sergio Sandrin and Song Ling and Yu Qin Li and McKenzie IFC},
  journal={Transplant immunology},
  year={2001},
  volume={9 1},
  pages={7-11}
}
Drug antibody conjugates can enhance the activity of monoclonal antibodies (MoAb) and idarubicin-MoAb conjugates have led to tolerance induction with antibodies which are inactive when used alone. It has been reported that, in mice, antibodies to ICAM-1 and LFA-1 have to be used together to induce tolerance to cardiac allografts; here we show that these monoclonal antibodies, conjugated to idarubicin, can lead to tolerance induction to cardiac allografts when used alone.